Crinetics Pharmaceuticals, Inc. (CRNX)
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $7.7M
- Net income
- -$465.3M
- Total assets
- $1.1B
- Market cap
- $3.5B
- Gross margin
- 86.0%
- Operating margin
- -6714.8%
- Net margin
- -6046.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $7.7M
- Cost of revenue
- $1.1M
- Gross profit
- $6.6M
- Operating expenses
- $523.4M
- Operating income
- -$516.8M
- Income tax
- $180.0K
- Net income
- -$465.3M
- EPS (basic)
- $-4.95
- EPS (diluted)
- $-4.95
Balance sheet
- Total assets
- $1.1B
- Current assets
- $1.0B
- Total liabilities
- $134.2M
- Current liabilities
- $85.1M
- Shareholders’ equity
- $992.1M
Cash flow
- Operating cash flow
- -$377.9M
- Investing cash flow
- $173.9M
- Financing cash flow
- $40.6M
- Net cash flow
- -$163.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $3.5B
- EPS (diluted)
- $-4.95
- Shares outstanding
- 41.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 18, 2018
Crinetics Pharmaceuticals, Inc. (CRNX) Stock Price
- Reported a net loss of $465.3M in FY2025.
- Revenue grew 10739% from FY2020 to FY2025.
- Gross margin of 86.0%, net margin -6046.2%.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Crinetics Pharmaceuticals, Inc..
Write a review
News about Crinetics Pharmaceuticals, Inc.
News & sentiment via Polygon.io
Crinetics Pharmaceuticals, Inc.: frequently asked questions
Is Crinetics Pharmaceuticals, Inc. an American company?
Crinetics Pharmaceuticals, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Crinetics Pharmaceuticals, Inc. headquartered?
Crinetics Pharmaceuticals, Inc. is headquartered in San Diego, California, United States.
Is Crinetics Pharmaceuticals, Inc. publicly traded?
Yes — Crinetics Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol CRNX on the NASDAQ.
What does Crinetics Pharmaceuticals, Inc. do?
Crinetics Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
When was Crinetics Pharmaceuticals, Inc. founded?
Crinetics Pharmaceuticals, Inc. was founded in 2008.
